Streetbeat News

DTCFF

Defence Therapeutics Inc

Industry

Research and Development in Biotechnology

Open

0.46

Mkt cap

19M

Volume

500

High

0.46

P/E Ratio

-2.13

52-wk high

2.07

Low

0.40

Div yield

N/A

52-wk low

0.40

Defence Therapeutics Inc. announces a new offering of unsecured convertible debentures to settle outstanding debt, aiming to raise up to CAD$1,570,000. The debentures bear an 8% interest rate and mature in November 2025.

Portfolio Pulse from

November 15, 2024 | 12:45 am

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has announced the appointment of Dr. Svetlana Selivanova, an expert in radiopharmaceuticals, to its board of directors. This move is expected to enhance the company's expertise in developing radiopharmaceuticals and ADC products.

Portfolio Pulse from

November 13, 2024 | 8:30 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.